These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 9428548)

  • 1. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration.
    Capellier G; Cornette C; Boillot A; Guinchard C; Jacques T; Blasco G; Barale F
    Crit Care Med; 1998 Jan; 26(1):88-91. PubMed ID: 9428548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
    van der Werf TS; Mulder PO; Zijlstra JG; Uges DR; Stegeman CA
    Intensive Care Med; 1997 Aug; 23(8):873-7. PubMed ID: 9310805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
    Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
    Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Sagripanti S; Manini P; Andreoli R; Cabassi A
    Crit Care Med; 2004 Dec; 32(12):2437-42. PubMed ID: 15599148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
    Boereboom FT; Ververs FF; Blankestijn PJ; Savelkoul TJ; van Dijk A
    Intensive Care Med; 1999 Oct; 25(10):1100-4. PubMed ID: 10551965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration.
    Heering P; Morgera S; Schmitz FJ; Schmitz G; Willers R; Schultheiss HP; Strauer BE; Grabensee B
    Intensive Care Med; 1997 Mar; 23(3):288-96. PubMed ID: 9083231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
    Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
    Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
    Guenter SG; Iven H; Boos C; Bruch HP; Muhl E
    Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
    Van der Werf TS; Fijen JW; Van de Merbel NC; Spanjersberg R; Möller AV; Ligtenberg JJ; Tulleken JE; Zijlstra JG; Stegeman CA
    Intensive Care Med; 1999 Dec; 25(12):1427-31. PubMed ID: 10660852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M; Tiula E; Takkunen O; Backman JT; Neuvonen PJ
    J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.
    de Pont AC; Oudemans-van Straaten HM; Roozendaal KJ; Zandstra DF
    Crit Care Med; 2000 Feb; 28(2):421-5. PubMed ID: 10708177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients.
    Bellomo R; Tipping P; Boyce N
    Crit Care Med; 1993 Apr; 21(4):522-6. PubMed ID: 8472571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
    Arzuaga A; Maynar J; Gascón AR; Isla A; Corral E; Fonseca F; Sánchez-Izquierdo JA; Rello J; Canut A; Pedraz JL
    J Clin Pharmacol; 2005 Feb; 45(2):168-76. PubMed ID: 15647409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of continuous venovenous hemofiltration with dialysis on lactate clearance in critically ill patients.
    Levraut J; Ciebiera JP; Jambou P; Ichai C; Labib Y; Grimaud D
    Crit Care Med; 1997 Jan; 25(1):58-62. PubMed ID: 8989177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure.
    Level C; Chauveau P; Guisset O; Cazin MC; Lasseur C; Gabinsky C; Winnock S; Montaudon D; Bedry R; Nouts C; Pillet O; Benissan GG; Favarel-Guarrigues JC; Castaing Y
    Crit Care; 2003 Dec; 7(6):R160-6. PubMed ID: 14624691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.